respiratori
viru
infect
rvi
increasingli
recogn
caus
signific
morbid
mortal
recipi
hematolog
stem
cell
transplant
hct
patient
hematolog
malign
hm
widespread
use
molecular
diagnost
epidemiolog
spectrum
clinic
diseas
infect
better
character
apart
influenza
current
avail
antivir
limit
efficaci
andor
associ
potenti
toxic
thu
emphas
import
prevent
strategi
articl
provid
review
epidemiolog
clinic
characterist
manag
prevent
rvi
hct
recipi
hm
patient
disclosur
keyword
respiratori
viru
infect
hematopoiet
stem
cell
transplant
rsv
influenza
parainfluenza
human
metapneumoviru
rhinoviru
coronaviru
morbid
associ
complic
respiratori
viru
infect
greater
hematopoiet
stem
cell
transplant
recipi
patient
hematolog
malign
immunocompet
individu
sever
ill
relat
degre
immunosuppress
molecular
microbiolog
test
gold
standard
diagnosi
allow
differenti
larg
overlap
clinic
syndrom
respiratori
virus
apart
influenza
circumst
respiratori
syncyti
viru
adenoviru
manag
support
prevent
key
focu
vaccin
influenza
avoid
ill
contact
complianc
principl
infect
control
infect
di
clin
n
studi
combin
pcr
tradit
laboratori
method
eg
cultur
direct
fluoresc
antibodi
enzym
immunoassay
b
pcrbase
studi
c
includ
allcaus
attribut
mortal
variabl
timefram
death
one
mortal
coinfect
patient
attribut
enterovirusrhinoviru
infect
report
incid
rvi
tabl
wide
rang
consequ
variat
screen
paramet
studi
popul
test
methodolog
season
trend
peak
patient
hm
hct
recipi
mirror
commun
rvi
activ
sometim
signific
yeartoyear
variabl
diseas
incid
sever
fig
older
studi
reli
less
sensit
method
viral
cultur
direct
fluoresc
antigen
like
underestim
incid
rvi
although
influenza
respiratori
syncyti
viru
rsv
typic
defin
season
mani
virus
occur
throughout
year
overlap
time
frame
see
fig
make
use
broadrang
diagnost
strategi
like
multiplex
polymeras
chain
reaction
pcr
critic
often
difficult
differenti
viru
type
base
season
clinic
present
respiratori
virus
transmit
direct
contact
fomit
aerosol
droplet
nuclei
envelop
virus
rsv
parainfluenza
viru
piv
coronaviru
cov
rhinoviru
influenza
ab
remain
viabl
fomit
hour
hour
transmiss
occur
direct
contact
infecti
materi
indirectli
fomit
inhal
particl
clinic
present
nonspecif
variabl
sever
spectrum
ill
rang
paucisymptomat
respiratori
failur
clinic
syndrom
categor
upper
respiratori
tract
infect
urti
rhinorrhea
nasal
congest
sinus
headach
otiti
media
sore
throat
malais
andor
fever
lower
respiratori
tract
infect
lrti
local
diffus
pneumonia
although
rvi
immunocompet
host
typic
acut
selflimit
present
hct
recipi
particular
atyp
sever
protract
major
present
fever
cough
fever
absent
approxim
third
case
normal
find
chest
auscult
lrti
present
greater
frequenc
immunocompromis
popul
tabl
incid
viral
infect
rate
lower
respiratori
tract
infect
diagnosi
mortal
rate
respiratori
viral
infect
consider
overlap
radiograph
find
rvi
rvi
infecti
noninfecti
entiti
plain
film
ct
imag
chest
radiograph
abnorm
includ
diffus
bilater
groundglass
infiltr
small
multifoc
nodul
bronchial
vascular
thicken
andor
airspac
consolid
major
immunocompromis
patient
radiograph
studi
perform
littl
half
radiograph
abnorm
time
diagnosi
sever
studi
radiolog
literatur
propos
specif
imag
featur
typifi
particular
rvi
exampl
retrospect
studi
ct
find
hct
recipi
found
infect
rsv
like
airwaycentr
pattern
diseas
treeinbud
opac
bronchial
wall
thicken
without
consolid
adenoviru
appear
multifoc
consolid
groundglass
opac
without
inflammatori
airway
find
although
featur
may
suggest
highli
specif
progress
urti
lrti
occur
variabl
frequenc
see
tabl
depend
rvi
type
host
factor
associ
increas
likelihood
fatal
outcom
virus
frequent
associ
lrti
includ
influenza
viru
piv
rsv
human
metapneumoviru
hmpv
risk
factor
associ
develop
lrti
includ
older
age
lymphopenia
earli
posttranspl
infect
myeloabl
condit
regimen
unmatch
donor
statu
condit
graftversushost
diseas
gvhd
necessit
increas
immunosuppress
variat
host
immun
statu
modul
molecular
cellular
respons
infect
provid
explan
differ
clinic
manifest
exampl
rsv
elicit
strong
neutrophil
respons
respiratori
tract
correspond
diseas
sever
wherea
cell
play
protect
role
promot
viral
clearanc
given
clinic
present
variou
rvi
nonspecif
microbiolog
test
requir
turn
inform
patientspecif
treatment
decis
isol
precaut
epidemiolog
investig
serolog
test
limit
applic
given
reinfect
common
time
humor
respons
viral
infect
often
detect
significantli
impair
immunocompromis
host
relianc
viral
cultur
hamper
prolong
turnaround
time
well
abandon
cell
vial
cultur
techniqu
clinic
laboratori
typic
favor
molecular
techniqu
said
viral
cultur
allow
strain
type
relev
allow
character
point
mutat
associ
antivir
drug
resist
antigen
detect
enzymebas
immunoassay
avail
respiratori
virus
lack
suffici
sensit
particularli
influenza
current
era
diagnosi
rvi
stem
cell
transplant
recipi
patient
hm
often
reliant
molecular
diagnost
strategi
comparison
methodolog
pcr
offer
rapid
turnaround
time
higher
sensit
abil
test
multipl
virus
singl
test
multiplex
platform
abil
detect
multipl
pathogen
base
specif
primer
revolution
molecular
diagnost
allow
panelbas
test
driven
clinic
syndrom
import
caveat
high
sensit
pcr
detect
viru
asymptomat
patient
repres
subclin
infect
asymptomat
shed
falseposit
test
result
pcr
perform
variou
specimen
type
eg
nasopharyng
np
wash
swab
oropharyng
swab
bronchoalveolar
lavag
bal
sampl
posit
neg
predict
valu
np
specimen
respect
compar
bal
specimen
studi
pair
np
bal
pcr
test
hct
hm
patient
lrti
variou
studi
use
quantit
viral
load
respiratori
specimen
correl
diseas
sever
predict
outcom
gaug
respons
treatment
said
practic
clinic
applic
quantit
pcr
limit
time
one
import
except
adenoviru
infect
case
viremia
predict
risk
dissemin
endorgan
diseas
well
surviv
although
yet
realm
routin
clinic
diagnost
nextgener
sequenc
techniqu
wholegenom
sequenc
hold
potenti
better
inform
rvi
outbreak
investig
exampl
health
care
set
tradit
pcrbase
diagnost
platform
coinfect
alloimmun
lung
syndrom
associ
rvi
hct
recipi
addit
impact
morbid
mortal
beyond
direct
attribut
risk
respiratori
tract
infect
coinfect
virus
superinfect
bacteria
fungi
well
describ
hct
recipi
rvi
rvi
seem
import
risk
factor
develop
invas
aspergillosi
allogen
hct
although
difficult
pars
contribut
viral
infect
milieu
immunosuppress
late
airflow
declin
occur
signific
proport
hct
recipi
rvi
first
day
transplant
particularli
affect
rsv
piv
infect
strong
associ
rvi
hct
develop
term
alloimmun
lung
syndrom
eg
idiopath
pneumonia
syndrom
bronchiol
obliteran
syndrom
bronchiol
obliteran
organ
pneumonia
turn
associ
increas
mortal
postul
rvi
earli
posttranspl
period
make
lung
target
alloimmun
outcom
rvi
hct
recipi
often
multifactori
natur
relat
direct
respiratori
impact
infect
aforement
complic
contribut
morbid
mortal
risk
mortal
rate
vari
among
differ
respiratori
virus
depend
clinic
present
well
underli
host
factor
risk
factor
increas
mortal
includ
lrti
mismatch
allogen
hct
infect
preengraft
phase
eg
health
careassoci
infect
index
transplant
hospit
highdos
steroid
time
lrti
infect
oxygen
requir
mechan
ventil
mortal
demonstr
particularli
high
rvi
outbreak
health
care
set
like
consequ
highrisk
natur
patient
segment
perhap
due
delay
diagnosi
set
detect
rvi
immedi
pretranspl
period
associ
lrti
decreas
surviv
day
mortal
greatest
symptomat
patient
overal
mortal
note
rvi
larg
contemporari
multicent
prospect
cohort
studi
allogen
hct
recipi
divers
infect
although
repres
crude
attribut
mortal
shortterm
outcom
oppos
longterm
outcom
like
relat
direct
effect
viral
infect
attribut
mortal
rvi
highest
lrti
piv
rsv
adenoviru
hmpv
influenza
virus
often
present
lrti
turn
highest
mortal
rate
see
tabl
attempt
develop
sever
score
system
predict
risk
lrti
progress
urti
lrti
mortal
rvi
hct
recipi
manag
rvi
consist
support
care
avail
applic
prompt
initi
antivir
therapi
although
signific
need
demonstr
clinic
benefit
relev
host
popul
challeng
new
antivir
drug
develop
use
adjuv
steroid
advis
highdos
steroid
gener
associ
increas
risk
progress
lrti
prolong
viral
shed
increas
mortal
consider
given
decreas
steroid
dose
whenev
feasibl
less
mg
perkgd
identif
rvi
immedi
pretranspl
set
rais
difficult
manag
question
given
risk
increas
complic
mortal
condit
transplant
ideal
delay
rvi
treat
andor
clinic
improv
said
decis
delay
transplant
requir
care
consider
acknowledg
risk
relaps
progress
underli
diseas
andor
issu
relat
donor
avail
transmiss
rvi
health
care
set
well
document
health
careassoci
outbreak
highlight
import
monitor
patient
visitor
sign
andor
symptom
rvi
symptomat
patient
isol
test
ill
visitor
health
care
worker
exclud
contact
vulner
popul
strict
complianc
infect
control
procedur
includ
isol
precaut
use
relev
person
protect
equip
hand
hygien
critic
prevent
spread
rvi
sever
guidelin
avail
eg
center
diseas
control
prevent
guidelin
outlin
specif
recommend
regard
isol
strategi
patient
suspect
document
rvi
place
droplet
contact
precaut
specif
isol
protocol
patient
rvi
vari
institut
institut
patient
educ
avoid
ill
contact
hand
hygien
influenza
vaccin
patient
close
contact
import
intervent
decreas
risk
acquisit
rvi
prolong
shed
rvi
occur
infrequ
host
popul
shed
week
greater
allogen
recipi
either
respiratori
viru
infect
human
rhinoviru
hrv
human
cov
hcov
infect
report
studi
prolong
asymptomat
shed
pose
great
challeng
infect
prevent
uncertainti
regard
degre
risk
transmiss
asymptomat
shedder
mani
center
opt
maintain
isol
precaut
sign
symptom
resolv
repeat
respiratori
viru
test
confirm
neg
influenza
singlestrand
envelop
rna
viru
belong
orthomyxovirida
famili
influenza
divid
subtyp
base
surfac
protein
hemagglutinin
neuraminidas
antigen
drift
shift
result
minor
major
chang
hemagglutinin
neuraminidas
respect
influenza
b
less
prone
antigen
variat
incid
infect
hct
recipi
hm
patient
driven
activ
influenza
commun
see
tabl
develop
lrti
associ
allogen
hct
statu
longer
durat
symptom
prior
present
neutropenia
lymphopenia
respiratori
coinfect
risk
factor
associ
increas
mortal
includ
older
age
lrti
hypoxemia
mechan
ventil
lymphopenia
neutropenia
delay
antivir
therapi
diseas
sever
outcom
vari
base
circul
strain
exemplifi
influenza
pandem
result
greater
ill
sever
higher
moral
season
influenza
lrti
occur
patient
mortal
rate
among
hct
recipi
approxim
earli
recognit
treatment
decreas
risk
progress
lrti
improv
surviv
antivir
treatment
given
earli
possibl
regardless
time
symptom
onset
present
patient
popul
delay
administr
shown
increas
progress
lrti
associ
wors
outcom
earli
administr
neuraminidas
inhibitor
nai
firstlin
agent
treatment
influenza
influenza
b
current
avail
nai
unit
state
includ
oral
oseltamivir
inhal
zanamivir
intraven
peramivir
standard
dose
oseltamivir
treatment
influenza
mg
twice
daili
day
data
support
use
highdos
oseltamivir
rather
standard
dose
optim
treatment
durat
hct
hm
popul
clear
prospect
trial
address
import
question
need
longer
durat
treatment
eg
day
consid
given
prolong
shed
risk
reactiv
remiss
particularli
occurr
infect
preengraft
period
potenti
benefit
longer
cours
antivir
therapi
must
balanc
concern
risk
emerg
resist
popul
era
pandem
preponder
patient
emerg
oseltamivirresist
viru
mutat
confer
crossresist
peramivir
zanamivir
sever
immunocompromis
mainli
hm
patient
hct
recipi
sever
novel
agent
develop
treatment
influenza
although
much
data
avail
hct
recipi
hm
patient
nai
laninamivir
octano
efficaci
oseltamivirresist
strain
current
use
japan
yet
food
drug
administr
approv
select
inhibitor
influenza
capdepend
endonucleas
recent
food
drug
administr
approv
uncompl
influenza
includ
resist
strain
yet
studi
complic
influenza
patient
popul
fontana
strasfeld
recombin
sialidas
fusion
protein
demonstr
activ
influenza
piv
complet
phase
ii
studi
immunocompet
adult
influenza
seem
potenti
altern
nairesist
influenza
favipiravir
viral
polymeras
inhibitor
approv
japan
use
nairesist
influenza
data
phase
ii
clinic
trial
favipiravir
uncompl
influenza
healthi
adult
unit
state
forthcom
http
clinicaltri
http
adjunct
corticosteroid
gener
advis
manag
influenza
data
retrospect
studi
hct
recipi
season
influenza
lowdos
mgkgd
highdos
mgkgd
steroid
larg
manag
gvhd
demonstr
signific
differ
develop
lrti
hypoxemia
need
mechan
ventil
death
trend
toward
lower
risk
lrti
group
lowdos
steroid
although
modest
dose
steroid
indic
anoth
caus
gvhd
may
continu
care
weigh
risk
benefit
steroid
start
specif
manag
influenza
infect
given
signific
morbid
associ
influenza
infect
oseltamivir
chemoprophylaxi
mg
daili
day
postexposur
durat
exposur
outbreak
set
strongli
consid
highrisk
patient
context
relev
exposur
outbreak
caution
regard
broad
use
prophylaxi
report
develop
oseltamivirresist
influenza
infect
hm
patient
oseltamivir
mg
twice
per
day
day
prophylaxi
exposur
subsequ
induct
chemotherapi
confirm
transmiss
oseltamivirresist
viru
patient
unit
although
immun
respons
vaccin
suboptim
particularli
hct
recipi
hm
patient
vaccin
cornerston
prevent
influenza
infect
attend
complic
receipt
influenza
vaccin
associ
decreas
risk
influenza
infect
hct
recipi
also
decreas
influenza
sever
complic
infect
occur
despit
vaccin
prospect
observ
studi
allogen
hct
recipi
receiv
trival
inactiv
influenza
vaccin
significantli
lower
preval
virolog
confirm
influenza
infect
vaccin
compar
nonvaccin
recipi
odd
ratio
decreas
risk
progress
lrti
lower
likelihood
influenzarel
hospit
compar
nonvaccin
state
individu
greater
month
age
without
contraind
includ
hct
recipi
hm
patient
receiv
influenza
vaccin
annual
vaccin
less
month
posttranspl
demonstr
result
poor
immun
respons
dose
influenza
vaccin
confer
superior
immun
compar
dose
standarddos
inactiv
influenza
vaccin
strongli
recommend
hct
recipi
greater
equal
month
posttranspl
earli
month
month
transplant
patient
without
gvhd
otherwis
requir
immun
suppress
commun
outbreak
live
attenu
influenza
vaccin
recommend
hct
recipi
immunocompromis
host
close
contact
pretranspl
vaccin
week
prior
condit
recommend
larg
strategi
provid
earli
posttranspl
protect
although
acknowledg
seroprotect
declin
rapidli
posttranspl
set
given
vulner
popul
suboptim
respons
vaccin
set
immun
compromis
vaccin
close
contact
health
care
worker
critic
arm
prevent
hm
patient
receiv
intens
chemotherapi
receiv
antibcel
antibodi
eg
rituximab
preced
month
unlik
respond
influenza
vaccin
strategi
improv
immun
respons
influenza
vaccin
includ
use
higher
antigen
dose
adjuv
vaccin
larg
studi
nonimmunocompromis
adult
greater
equal
year
age
highdos
trival
vaccin
result
significantli
higher
seroprotect
rate
better
protect
laboratoryconfirm
influenza
infect
standarddos
vaccin
phase
studi
compar
highdos
standarddos
trival
inactiv
vaccin
adult
hct
recipi
demonstr
higher
rate
seroprotect
titer
highdos
group
small
studi
adjuv
vaccin
multidos
vaccin
shown
promis
improv
immunogen
certain
influenza
strain
decreas
hospit
admiss
reduc
mortal
parainfluenza
piv
negativesens
singlestrand
envelop
rna
virus
paramyxovirida
famili
distinct
serotyp
includ
serotyp
respiroviru
genu
serotyp
rubulaviru
genu
epidemiolog
clinic
featur
piv
serotyp
vari
wide
although
circul
yearli
biennial
pattern
incid
symptomat
piv
adult
pediatr
hct
recipi
see
tabl
report
incid
piv
infect
hct
recipi
may
fals
low
due
larger
percentag
asymptomat
subclin
infect
compar
rvi
predomin
serotyp
associ
infect
hm
patient
hct
recipi
multipl
studi
demonstr
comparison
serotyp
associ
sever
infect
increas
risk
progress
lrti
higher
mortal
infect
associ
increas
mortal
adjust
age
cmv
serostatu
donor
type
underli
diseas
larg
systemat
review
studi
piv
infect
hm
patient
hct
recipi
lrti
occur
patient
respect
risk
factor
lrti
includ
allogen
hct
earli
posttranspl
infect
lymphopenia
neutropenia
use
steroid
urti
phase
retrospect
studi
hct
recipi
span
decad
found
associ
progress
urti
lrti
serotyp
infect
presenc
monocytopenia
greater
mg
kg
steroid
prior
diagnosi
copathogen
detect
patient
lack
risk
factor
progress
lrti
wherea
progress
risk
increas
greater
risk
factor
present
need
mechan
ventil
lrti
surviv
onset
mechan
ventil
although
overal
mortal
piv
lrti
high
transplant
mortal
decreas
time
transplant
pivassoci
mortal
wide
variabl
report
high
copathogen
see
tabl
current
licens
antivir
agent
treatment
piv
infect
despit
data
support
vitro
piv
activ
numer
retrospect
studi
shown
lack
benefit
aerosol
system
ribavirin
without
intraven
immunoglobulin
ivig
improv
outcom
establish
lrti
prevent
progress
urti
lrti
decreas
viral
shed
report
success
treatment
hct
recipi
seriou
piv
infect
investig
agent
data
phase
studi
includ
hct
recipi
hm
patient
forthcom
http
rsv
singlestrand
envelop
negativesens
rna
viru
within
pneumovirida
famili
hmpv
two
antigen
subtyp
b
circul
season
either
simultan
altern
rsv
arguabl
one
respiratori
viru
infect
associ
highest
diseas
sever
mortal
risk
hct
recipi
age
lymphopenia
neutropenia
myeloabl
condit
regimen
preengraft
infect
recent
hct
use
marrow
cord
blood
graft
sourc
mismatch
unrel
donor
gvhd
highdos
steroid
delay
diagnosi
detect
viral
rna
serum
associ
rsv
lrti
rsvassoci
mortal
attempt
made
develop
immunodefici
score
index
rsvinfect
hct
recipi
quantifi
risk
lrti
mortal
assist
decis
make
initi
antivir
therapi
treatment
rsv
infect
hct
recipi
remain
area
signific
controversi
absenc
highqual
prospect
data
toxic
cost
avail
therapi
heterogen
host
factor
contribut
uncertainti
regard
best
approach
rsv
manag
preponder
exist
literatur
draw
singlecent
retrospect
studi
inher
bias
limit
ribavirin
guanosin
analog
avail
aerosol
intraven
oral
form
import
toxic
includ
myelosuppress
aerosol
form
bronchospasm
aerosol
ribavirin
extrem
costli
light
orphan
drug
statu
complic
administ
given
potenti
teratogen
requir
use
person
protect
equip
special
air
flow
environ
palivizumab
rsvspecif
recombin
monoclon
antibodi
polyclon
ivig
use
combin
ribavirin
although
contribut
rsv
treatment
controversi
difficult
quantifi
cost
substanti
particularli
palivizumab
rsv
monotherapi
palivizumab
neither
support
literatur
recommend
rsvspecif
ivig
longer
avail
histor
numer
public
demonstr
benefit
aerosol
ribavirin
alon
antibodybas
therapi
rsv
decreas
rate
progress
urti
lrti
decreas
mortal
studi
howev
sever
limit
basi
singlecent
retrospect
studi
design
random
control
multicent
trial
aerosol
ribavirin
rsv
urti
hct
recipi
discontinu
slow
accrual
failur
meet
statist
signific
primari
endpoint
progress
lrti
trend
toward
decreas
viral
load
time
observ
group
assign
ribavirin
definit
prospect
data
regard
use
aerosol
ribavirin
rsv
infect
popul
lack
unlik
forthcom
system
ribavirin
oral
intraven
rout
without
antibodybas
therapi
explor
less
toxic
altern
nebul
ribavirin
treatment
rsv
small
case
seri
demonstr
toler
suggest
potenti
efficaci
recent
retrospect
data
compar
oral
ribavirin
aerosol
ribavirin
provid
increas
evid
support
use
oral
ribavirin
safe
costeffect
potenti
efficaci
altern
aerosol
ribavirin
hct
recipi
sever
immunocompromis
host
rsv
infect
rsv
treatment
decis
complic
take
account
host
factor
inform
risk
progress
lrti
diseas
sever
present
drug
toxic
sideeffect
profil
cost
although
avail
literatur
support
use
respiratori
viru
infect
ribavirin
highrisk
patient
rsv
infect
profound
limit
gener
treatment
algorithm
uncontrol
studi
end
small
case
seri
describ
low
morbid
progress
lrti
mortal
pediatr
hct
recipi
rsv
infect
manag
without
ribavirin
mainten
ivig
without
palivizumab
sever
small
molecul
antivir
agent
earli
phase
develop
studi
rsv
infect
membran
fusion
rna
synthesi
import
drug
target
presatovir
novel
oral
fusion
protein
inhibitor
show
promis
earli
phase
clinic
trial
fail
demonstr
reduct
nasal
rsv
viral
load
symptom
durat
lung
transplant
recipi
similarli
asvasiran
small
interf
rna
target
rsv
replic
progress
due
limit
impact
viral
paramet
lack
improv
symptomat
patient
lumicitabin
rna
polymeras
inhibitor
associ
reduct
viral
load
clinic
sever
compar
placebo
phase
ii
rsv
challeng
studi
healthi
adult
although
role
agent
await
clarif
target
popul
investig
agent
phase
ii
studi
hct
recipi
name
nanobodi
fusion
inhibitor
http
http
nonnucleosid
rsv
l
protein
polymeras
inhibitor
http
rsv
vaccin
current
avail
although
clinic
trial
ongo
adenovirus
famili
nonenvelop
doublestrand
dna
virus
describ
serotyp
categor
subgroup
speci
g
certain
serotyp
associ
particular
clinic
syndrom
reflect
virusspecif
tissu
tropism
cellular
receptor
adenovirus
nonenvelop
virus
surviv
extend
period
environment
surfac
resist
kill
quaternari
ammonium
compound
disinfect
wide
use
health
care
set
transmiss
occur
via
aerosol
droplet
fomit
rvi
well
fecalor
spread
exposur
infect
tissu
blood
product
infect
hct
recipi
sever
immunocompromis
host
consequ
new
acquisit
reactiv
endogen
infect
spectrum
clinic
diseas
hct
recipi
broad
includ
urti
andor
lrti
enterocol
hepat
nephriti
hemorrhag
cystiti
meningoenceph
respiratori
tract
infect
caus
often
subgroup
b
c
incid
gener
higher
pediatr
popul
dissemin
diseas
occur
patient
associ
allogen
hct
receipt
tcelldeplet
graft
infect
earli
posttranspl
period
presenc
gvhd
use
system
steroid
lymphopenia
presenc
viremia
well
height
viral
load
meaning
predictor
risk
invas
dissemin
diseas
well
mortal
overal
mortal
syndrom
high
especi
patient
pneumonia
dissemin
diseas
particularli
recipi
celldeplet
graft
monitor
pcr
preemptiv
antivir
treatment
advoc
expert
support
sever
studi
highrisk
hct
recipi
notabl
pediatr
popul
said
studi
includ
prospect
studi
adult
pediatr
nontcelldeplet
recipi
retrospect
studi
pediatr
recipi
variou
graft
type
condit
regimen
fail
demonstr
benefit
monitor
preemptiv
treatment
current
antivir
formal
indic
adenoviru
infect
cidofovir
nucleotid
analog
inhibit
dna
polymeras
activ
serotyp
adenoviru
vitro
anim
data
demonstr
virolog
clinic
activ
respect
human
data
support
cidofovir
treatment
adenoviru
infect
hct
recipi
draw
larg
retrospect
studi
demonstr
lower
mortal
rate
treat
compar
untreat
patient
pharmacolog
disadvantag
cidofovir
includ
activ
excret
unchang
drug
urin
result
nephrotox
low
bioavail
limit
concentr
activ
phosphoryl
compound
infect
cell
furthermor
toxic
cidofovir
often
dose
limitingmainli
nephrotox
myelosuppress
ocular
toxic
brincidofovir
oral
lipid
ester
cidofovir
improv
bioavail
better
safeti
profil
investig
agent
studi
treatment
adenoviru
infect
hct
recipi
although
uncontrol
seri
suggest
efficaci
toler
brincidofovir
treat
adenoviru
viremia
diseas
hct
recipi
random
placebocontrol
phase
ii
trial
fail
meet
primari
endpoint
reduct
treatment
failur
demonstr
signal
diarrhea
group
assign
brincidofovir
although
vitro
data
suggest
ribavirin
activ
adenoviru
vivo
data
born
clinic
util
clearanc
viremia
surviv
highli
associ
lymphocyt
reconstitut
mind
adopt
tcell
transfer
adenovirusspecif
donor
cell
remain
area
activ
investig
said
despit
well
decad
work
adenovirusspecif
cytotox
lymphocyt
approach
far
routin
clinic
applic
concert
consider
antivir
treatment
seriou
adenoviru
infect
hct
recipi
decreas
immun
suppress
abl
also
entertain
hmpv
larg
envelop
negativesens
rna
viru
within
pneumovirida
famili
rsv
hmpv
recent
describ
viral
infect
identifi
aid
molecular
techniqu
report
incid
hmpv
increas
time
concert
improv
molecular
diagnost
capabl
knowledg
diseas
spectrum
continu
evolv
increas
recognit
hmpv
caus
rvi
immunocompromis
host
popul
prospect
studi
urti
lrti
hm
patient
hct
recipi
retrospect
analysi
hmpv
demonstr
overal
incid
lrti
death
overal
onethird
lrti
retrospect
studi
span
decad
identifi
case
hmpv
hct
recipi
lrti
occur
overal
progress
lrti
high
steroid
dose
greater
equal
mgkg
lymphopenia
time
present
urti
recent
systemat
review
literatur
similarli
found
low
overal
virusassoci
mortal
rate
substanti
higher
mortal
lrti
although
vitro
data
case
seri
case
report
describ
use
ribavirin
without
ivig
preponder
data
retrospect
natur
fail
demonstr
protect
effect
ribavirin
andor
ivig
prevent
hmpv
lrti
mortal
earli
perhap
promis
area
hmpv
drug
discoveri
research
novel
use
small
interf
rna
human
bocaviru
hbov
small
dna
viru
within
parvovirida
famili
hbov
first
describ
molecular
viru
screen
np
aspir
respiratori
viru
infect
hospit
children
lrti
although
studi
immunocompet
children
lrti
demonstr
incid
high
data
hct
popul
indic
infrequ
infect
prospect
singlecent
studi
spain
span
month
found
hbov
virolog
document
rvi
episod
consecut
allogen
hct
recipi
interestingli
coinfect
anoth
respiratori
viru
diseas
sever
substanti
case
lrti
believ
like
caus
enterovirusrhinoviru
death
respiratori
failur
affect
patient
viral
dissemin
document
transplant
recipi
detect
hbov
blood
stool
given
frequenc
coinfect
mild
diseas
sever
mani
question
remain
regard
pathogen
potenti
hbov
hct
recipi
immunocompromis
host
mode
transmiss
hbov
well
character
specif
antivir
treatment
hbov
infect
cov
positivesens
singlestrand
envelop
rna
virus
coronavirida
famili
cov
widespread
among
bird
anim
cov
alpha
beta
genera
associ
human
infect
alphacov
includ
betacov
includ
middl
east
respiratori
syndrom
cov
sever
acut
respiratori
syndrom
cov
cocircul
nonsumm
month
prospect
surveil
studi
hct
recipi
detect
hcov
patient
first
year
posttranspl
approxim
half
patient
asymptomat
infrequ
develop
lrti
suggest
infect
common
typic
sever
surprisingli
prospect
retrospect
studi
symptomat
cohort
point
higher
variabl
morbid
mortal
rvi
copathogen
detect
hcov
frequent
make
interpret
attribut
mortal
complic
said
welldocu
case
sever
even
fatal
hcov
lrti
hm
patient
hct
recipi
specif
antivir
treatment
cov
infect
hrv
small
singlestrand
rna
virus
member
picornavirida
famili
genu
enteroviru
rhinovirus
classifi
speci
base
capsid
featur
sequenc
b
c
rhinovirus
circul
yearround
although
season
cluster
speci
contemporari
studi
use
molecular
diagnost
techniqu
rhinoviru
frequent
detect
rvi
hm
patient
hct
recipi
import
recogn
limit
current
diagnost
platform
inabl
differenti
rhinoviru
enteroviru
clinic
present
highli
variabl
report
literatur
patient
urti
although
sizabl
minor
lrti
larg
contemporari
studi
symptomat
hm
patient
hrv
infect
approxim
present
lrti
present
urti
stage
progress
lrti
within
day
suggest
symptomat
lrti
uncommon
rvi
hrv
especi
like
mani
studi
overestim
lrti
rate
fail
account
greater
tendenc
patient
seek
medic
care
set
sever
ill
although
studi
found
associ
hrv
sever
lrti
speci
type
consist
find
coinfect
common
particularli
lrti
make
interpret
attribut
morbid
mortal
challeng
larg
retrospect
studi
approxim
hct
recipi
hrv
infect
span
decad
overal
mortal
subject
lrti
significantli
associ
low
monocyt
count
oxygen
requir
diagnosi
steroid
dose
greater
mgkgd
diagnosi
surviv
affect
presenc
copathogen
rvi
earli
posttranspl
infect
associ
greater
diseas
sever
specif
antivir
treatment
hrv
infect
